We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 31 for:    alpharadin | Recruiting, Not yet recruiting, Available Studies

Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases

This study is currently recruiting participants.
Verified November 2017 by Bayer
Sponsor:
ClinicalTrials.gov Identifier:
NCT02803437
First Posted: June 17, 2016
Last Update Posted: November 14, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Bayer
  Purpose
This study is a Japanese post-marketing surveillance (PMS) which is required by the regulatory authorities. General objective of PMS is to confirm the clinical usefulness, especially the safety profile of a drug under the routine clinical practice.

Condition Intervention
Prostatic Neoplasms, Castration-Resistant Drug: Radium-223 dichloride (Xofigo, BAY 88-8223)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • Number of adverse events as a measure of safety [ Time Frame: Up to 6 months ]
    Events will be summarized by frequency tables (e.g. absolute and relative frequencies) using the MedDRA coding system

  • Number of Adverse drug reactions as a measure of safety [ Time Frame: Up to 6 months ]
    Events will be summarized by frequency tables (e.g. absolute and relative frequencies) using the MedDRA coding system


Secondary Outcome Measures:
  • Change in laboratory findings (e.g. ALP, bone markers) [ Time Frame: From Baseline up to 6 month ]
  • Change in Analgesic use as a surrogate of pain status [ Time Frame: From Baseline up to 6 month ]

Estimated Enrollment: 300
Actual Study Start Date: July 21, 2016
Estimated Study Completion Date: December 31, 2018
Estimated Primary Completion Date: June 30, 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Xofigo / Cohort 1
Patients suffered from CRPC with bone metastases are enrolled after the physician's decision of Xofigo treatment under the routine clinical practice.
Drug: Radium-223 dichloride (Xofigo, BAY 88-8223)
Xofigo treatment will be performed according to the product label in Japan under the routine clinical practice.

Detailed Description:

This is a local, non-interventional, multi-center, single-cohort study using primary data of patients treated with Xofigo for the indication of castration resistant prostate cancer (CRPC) with bone metastases. A total of 300 patients (valid for safety analysis) are enrolled within 18 months.

During the observation period, safety and effectiveness information is collected. Since patient's visit occurs under the routine clinical practice, the study protocol does not define exact referral dates for those visits. The physician records patient data as defined in the protocol.

The outcome variables for the primary objective are Treatment Emergent Adverse Event (TEAEs) and Adverse Drug Reaction (ADRs). The outcome variables for secondary objectives include laboratory findings (e.g. Alkaline Phosphatase [ALP], bone markers if measured) and pain status (analgesic utility).

The results of this study have to be submitted to the Japanese regulatory authorities as a part of the re-examination package after the completion of the re-examination period (8 years). This study is conducted in accordance with Article 14-4 (re-examination) of the Pharmaceutical Affairs Law, and Good Post-marketing Surveillance Practice from a ministerial ordinance of Ministry of Health, Labor and Welfare in Japan.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients suffered from castration resistant prostate cancer with bone metastases
Criteria

Inclusion Criteria:

  • Patients suffered from CRPC with bone metastases
  • Patients for whom the decision to initiate treatment with Xofigo is made as per physician's routine clinical practice.
  • Xofigo treatment naïve

Exclusion Criteria:

  • Patients treated Xofigo previously
  • Patients participating in an investigational program with interventions outside of routine clinical practice
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02803437


Contacts
Contact: Bayer Clinical Trials Contact clinical-trials-contact@bayer.com

Locations
Japan
Recruiting
Many locations, Japan
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT02803437     History of Changes
Other Study ID Numbers: 18212
First Submitted: June 14, 2016
First Posted: June 17, 2016
Last Update Posted: November 14, 2017
Last Verified: November 2017

Keywords provided by Bayer:
Castration-resistant prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Radium Ra 223 dichloride
Antineoplastic Agents